Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK2340272A in Children
NCT00972517Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Q-Pan H1N1 in influenza, sponsored by GSK. Primary endpoints: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against the Flu A/California/7/2009 (H1N1) Vaccine Strain at Day 42, Number of Seroconverted Subjects for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain at Day 42 and 2 more. Started Sep 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00972517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972517.